Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.

Twenty-eight compounds, including 24 structurally related derivatives of tariquidar synthesized in our laboratory, and four XR compounds, reported by Xenova group Ltd, were investigated by the Hoechst 33342 and Calcein AM functional assays for estimation of their inhibitory effects on the transport activity of P-glycoprotein (P-gp). A high correlation between the effects obtained in both assays was observed at the substrate concentrations used. The analyses of kinetics data from experiments at different substrate concentrations revealed non-competitive inhibition in the Calcein AM assay and competitive inhibition in the Hoechst 33342 assay. The 3D structures of the compounds were further aligned on Hoechst 33342 using flexible and pharmacophore alignments. The results suggested that inhibitors could interact with the H-binding site of P-gp and this could potentially be achieved by different ways of binding. The best 3D-QSAR models, generated by CoMFA and CoMSIA, yielded an internal predictive squared correlation coefficient higher than 0.8 and included electrostatic, steric, hydrogen bond acceptor, and hydrophobic fields. Validation of the models on an external test set of 30 XR compounds gave predictive squared correlation coefficients of up to 0.66. An excellent correspondence between the experimental and modeled activities of the test compounds was observed. The models can be used for prediction and rational design of new P-gp inhibitors.

[1]  I. Pajeva,et al.  New functional assay of P-glycoprotein activity using Hoechst 33342. , 2007, Bioorganic & medicinal chemistry.

[2]  Elizabeth Fox,et al.  Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor , 2007, Expert review of anticancer therapy.

[3]  R. Callaghan,et al.  Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. , 2004, European journal of cancer.

[4]  A. Safa,et al.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. , 2004, Current medicinal chemistry. Anti-cancer agents.

[5]  Christoph Globisch,et al.  Molecular Modeling of P-Glycoprotein and Related Drugs , 2005, Medicinal Chemistry Research.

[6]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[7]  Lakshmi P Kotra,et al.  A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators. , 2006, Journal of medicinal chemistry.

[8]  I. Pajeva,et al.  Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. , 1998, Journal of medicinal chemistry.

[9]  W. Priebe,et al.  Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. , 2001, Current medicinal chemistry.

[10]  R. Reilly,et al.  In vitro and in vivo evaluation of WK‐X‐34, a novel inhibitor of P‐glycoprotein and BCRP, using radio imaging techniques , 2006, International journal of cancer.

[11]  B. David Silverman The Thirty-one Benchmark Steroids Revisited: Comparative Molecular Moment Analysis (CoMMA) with Principal Component Regression , 2000 .

[12]  R. Reilly,et al.  Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties , 2006, Cancer Chemotherapy and Pharmacology.

[13]  Christoph Globisch,et al.  Structure-function relationships of multidrug resistance P-glycoprotein. , 2004, Journal of medicinal chemistry.

[14]  P. Charlton,et al.  Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. , 1999, Bioorganic & medicinal chemistry letters.

[15]  C. Higgins,et al.  The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein , 1999, British journal of pharmacology.

[16]  P. Charlton,et al.  In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. , 2001, Cancer research.

[17]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  C. Higgins,et al.  Communication between multiple drug binding sites on P-glycoprotein. , 2000, Molecular pharmacology.

[19]  V. Ling,et al.  Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. , 1997, European journal of biochemistry.

[20]  J. Robert,et al.  Multidrug resistance reversal agents. , 2003, Journal of medicinal chemistry.

[21]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[22]  F. Sharom,et al.  Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet. , 2002, Biochemistry.

[23]  Michael Wiese,et al.  Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. , 2006, Bioorganic & medicinal chemistry.